MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.
Annals of hematology
View this publicationAnnals of hematology
View this publicationHemaSphere
View this publicationEMBO molecular medicine
View this publicationAnnals of hematology
View this publicationLeukemia
View this publicationBritish journal of haematology
View this publicationPublication categories: Top publication
The Journal of experimental medicine
View this publicationSTAR protocols
View this publicationBlood advances
View this publicationiScience
View this publication